




National Institute for  
Health Research

# The role of evidence evaluation in facilitating successful market adoption

John Simpson

14th March 2018



Biobanks




Genomics & Genetics



**NHS**  
National Institute for Health Research



Newcastle Laboratories



CIVI

newcastle  
**node**  
molecular pathology

NIHR Newcastle  
In Vitro Diagnostic  
Co-operative



Welcome  
**DNE**  
DIAGNOSTICS NORTH EAST

Innovation  
Observatory



**NHS**  
National Institute for Health Research

**NORTH EAST & NORTH CUMBRIA**  
Academic Health Science Network



>120 interactions with industry

Co-applicant or lead on grants with total value of >£12M

Delivery to time and target of multicentre clinical studies

Embedded within a network of key stakeholders  
(particularly facilitated by AHSN and NuTH)

Academic outputs, interaction with patient groups

**Training of 3 dedicated evaluation methodologists  
and 1 clinical scientist**

# The NIHR MICs



National Institute for Health Research

Leading NHS organisations have been awarded funding to host **NIHR MICs**.

Over £14 million has been awarded across 11 NIHR MICs!

NIHR Medtech and In vitro diagnostics Co-operatives (MICs) build expertise and capacity in the NHS to develop new medical technologies and provide evidence on commercially-supplied in vitro diagnostic (IVD) tests.

## Ncl MIC is a partnership between:

- NuTH
- Newcastle University

## Facilitates evidence on:

- Clinical validity
- Clinical utility
- Value for money
- Affordability

of *in vitro* diagnostic medical devices (IVDs) and diagnostic medical technologies



# NCL MIC Themes



## Newcastle IVD Co-operative:


### *Clinical themes:*

- **Ageing and long term chronic conditions**— Led by Dr James Frith
- **Precision Medicine** - Led by Professor Nick Reynolds
- **Infection** – Led by Dr Ashley Price

### *Methodological themes:*


- **Early decision analysis and economic modelling**
- **Clinical decision aid development**
- **Imperfect reference standard methodology development**

# Evidence development pathway: overview



# Care pathway analysis

- Current pathway
- Potential changes to the current pathway
- Compare current and “new” pathway
- Identification of the improvement(s) / benefits / role
- Helps you to identify:
  - Patient population
  - Clinical setting



# Mologic Ltd – Headstart test for exacerbation of COPD




## Completion of Phase 1 Innovate UK –

## Stratified Medicine SBRI contract+

Confirmed clinical need via patient, clinician and commissioner interviews

- Evaluation of patient usability
- Care pathway analysis
- Early economic modelling
- Definition of the patient population
- Identification of potential barriers to adoption and possible adoption strategies



# Alere Ltd – Rapid, near patient test for Influenza A and B



National Institute for Health Research


Multicentre study: Sheffield Royal Hallamshire and Teaching Hospitals, Doncaster Royal Infirmary and the Newcastle Royal Victoria Infirmary

- Recruitment – Winter 14/15
- Target ~800 patients
- Primary aim: **sensitivity and specificity of Alere™ i NPT**
- Secondary aims:
  - Impact of rapid test on use of assessment suite isolation facilities and onward transmission of influenza.
  - Cost-implications.




## Time delay for PCR result in:

- DGH > 5 days
- Hosp with offsite lab > 40 hours
- Hosp with onsite lab >25 hours



# The innovation pathway



1. We support invention and discovery, new targets, new tests, new testing methodologies
2. We evaluate technology and devices and provide bespoke advice on potential
3. We have the potential to provide a route to market for transformative technology within an outstanding healthcare system